


Cortese D, Konstantin C, Guglielmo S, Wang LZ, Golding BT, Cano C, Fruttero R. [Synthesis and biological evaluation of new N²-substituted 2,4-diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and related 5-cyano-NNO-azoxy derivatives as \(CDK2\) Inhibitors](#). *ChemMedChem* 2016

Copyright:

This is the peer reviewed version of the following article: Cortese D, Konstantin C, Guglielmo S, Wang LZ, Golding BT, Cano C, Fruttero R. [Synthesis and biological evaluation of new N²-substituted 2,4-diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and related 5-cyano-NNO-azoxy derivatives as \(CDK2\) Inhibitors](#). *ChemMedChem* 2016, which has been published in final form at <http://dx.doi.org/10.1002/cmdc.201600108> This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Date deposited:

13/07/2016



This work is licensed under a [Creative Commons Attribution-NonCommercial 3.0 Unported License](#)

Synthesis and biological evaluation of new *N*²-substituted 2,4-diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and related 5-cyano-*NNO*-azoxy derivatives as CDK2 Inhibitors.

Daniela Cortese,^[a] Konstantin Chegaev,^[a] Stefano Guglielmo,^[a] Lan Z. Wang,^[b] Bernard T. Golding,^[c] Céline Cano,^[c] and Roberta Fruttero^{*,[a]}

[a] Dr. D. Cortese, Dr. K. Chegaev, Dr. S. Guglielmo, Prof. R. Fruttero
Department of Drug Science and Technology
Università degli Studi di Torino
Via P. Giuria 9, 10125 Turin, Italy
E-mail: roberta.fruttero@unito.it

[b] L. Z. Wang
Northern Institute for Cancer Research
Paul O'Gorman Building, Medical School
Newcastle University
Framlington Place, Newcastle Upon Tyne
NE2 4HH

[c] Prof. B. T. Golding, Dr. C. Cano
Northern Institute for Cancer Research
School of Chemistry, Bedson Building
Newcastle University
Newcastle Upon Tyne
NE1 7RU


Supporting information for this article is given via a link at the end of the document.

Abstract: The potent and selective Cyclin-Dependent Kinase 2 (CDK2) inhibitor NU6027 (6-cyclohexylmethoxy-5-nitroso-2,4-diaminopyrimidine) was used as the lead for the synthesis of a series of analogues in order to provide further insights into the structure activity relationships for 2,4-diaminopyrimidine CDK2 inhibitors. Aliphatic amino substituents were introduced at position 2. The use of linear or less sterically hindered amines gave rise to compounds endowed with slightly improved activity with respect to the lead; on the other hand, the compounds were the less active when a bulkier amino substituent was used. Substitution of the 5-nitroso group with the 5-cyano-*NNO*-azoxy moiety afforded a new class of inhibitors whose activity against CDK2 was similar to that of the nitroso series. The most active nitroso compound was **8b** ($IC_{50} = 0.16 \mu\text{M}$) while in the 5-cyano-*NNO*-azoxy series the most active compound was **9b** ($IC_{50} = 0.30 \mu\text{M}$). Taken as a whole these new analogues of NU6027 enhance understanding of the structure activity relationships for 2,4-diaminopyrimidine CDK2 inhibitors.

Cyclin-Dependent Kinases (CDKs) are serine/threonine kinases which display an abnormal activity in many kinds of tumours.^[1] This family of kinases is represented by eleven members (CDK1-CDK11) and related cyclins.^[2] Today, there is a great interest in small molecules able to behave as inhibitors of these enzymes as potential anticancer drugs. In the past decade, many such compounds belonging to different chemical classes have been developed.^[3] Among these inhibitors, an interesting type is represented by 2,4-diamino-6-cyclohexylmethoxy-5-nitrosopyrimidine (**1**) (NU6027) (Chart 1), a competitive inhibitor

of CDK1 and CDK2 isoforms with respect to ATP ($CDK2 IC_{50} = 2.2 \mu\text{M}$).^[3-5] Owing to the intramolecular hydrogen bond between the adjacent 5-nitroso and 4-amino groups, this compound assumes a pseudo-purine geometry, which is reminiscent of the structure of 6-(cyclohexylmethoxy)-9*H*-purine (**2**) (NU2058) (Chart 1), an early relatively potent CDK1 and CDK2 inhibitor ($CDK2 K_i = 12 \mu\text{M}$).^[6] Compound **1** can interact with the ATP-binding site of the enzymes by a triplet of hydrogen bonds (for CDK2: 2-NH₂ to Leu-83 (CO), N³ to Leu-83 (NH), 4-NH₂ to Glu-81 (CO)).^[4] These interactions exactly reproduce those of **2**. An extended series of analogues of **1** modified at the 2-, 5- and 6-position(s) were synthesized in order to shed light on the structure-activity relationships (SAR) in this lead compound.^[3, 4] In a recent paper we described a new pyrimidine scaffold, the 2,4-diamino-5-(cyano-*NNO*-azoxy)-6-(cyclohexylmethoxy)pyrimidine (**3**) (Chart 1), endowed with potent inhibitory CDK2 activity.^[7] This substance can be formally obtained by substitution of the nitroso group of **1** with the cyano-*NNO*-azoxy moiety, which is present in the antibiotic "calvatic acid" (4-[(*Z*)-cyano-*NNO*-azoxy]benzoic acid) isolated for the first time from cultural broth of *Calvatia lilacina*.^[8] This unusual functional group has been used to design several bioactive compounds, such as antimicrobial and antitumor agents, enzyme inhibitors, and calcium channel blockers.^[9-13] The cyano-*NNO*-azoxy moiety displays an electron withdrawing property very similar to that of the nitroso group ($\sigma_{p,NO} = 0.91$; $\sigma_{p,ONNOCN} = 0.89$), whereas it is endowed with different lipophilicity ($\pi_{NO} = -1.20$; $\pi_{ONNOCN} = -0.26$) and steric properties.^[14,15]

A molecular modelling study has suggested a role for a conserved water molecule in stabilizing the bioactive pose of **3** in the interaction with the ATP site of the enzyme. Preliminary SAR showed that the substitution of the cyano group of **3** with




other electron withdrawing moieties induced a significant decrease in activity, whilst the introduction at the 2-NH₂ group of a *p*-methylaminosulfonyl-substituted phenyl ring gave rise to a product whose potency fell in the nM range.^[7] In this study a detailed description of the synthetic routes to a series of new *N*²-substituted examples of this structural class (**9a-i**) and of their 5-nitroso precursors (**8a-i**) is reported and the influence of the lateral chain at this position on the their CDK2 inhibitory activity is discussed.

Chart 1. Reference compounds.


Scheme 1. Reagents and conditions: a) (bromomethyl)cyclohexane, 140°C μ W heating, 16 min; b) mCPBA, CH₂Cl₂, RT, 18 h; c) RNH₂, 120°C, μ W heating; d) R²ONO, DMSO, RT; e) NH₂CN, (diacetoxyiodo)benzene (IBA), CH₃CN, RT, 2 h.

A series of *N*²-substituted 2,4-diamino-6-cyclohexylmethoxy-5-



nitrosopyrimidines (**8a-i**) was prepared using a synthetic strategy (Scheme 1) similar to that described previously by Marchetti *et al.*^[5] Some modifications improved the reported reaction conditions. Alkylation of 6-amino-2-thioxo-2,3-dihydropyrimidin-4(1*H*)-one (**4**) was performed using (bromomethyl)cyclohexane. At variance with the previous synthetic strategy, (bromomethyl)cyclohexane was used to enable the concomitant alkylation at 2- and 4- positions. In addition, the use of microwave heating (μ W) afforded the desired product **5** in 16 min at 140°C. Oxidation of **5** with mCPBA gave the corresponding cyclohexylmethylsulfone **6**. The nucleophilic displacement of cyclohexylsulfonyl group in **6** with diverse aliphatic amines was performed in an organic solvent (diglyme

or THF) using microwave heating and in some cases, a Lewis



acid such as Yb(OSO₂CF₃)₃ was added to improve the yield. The *N*²-substituted 4-amino-6-cyclohexylmethoxypyrimidines (**7a-i**) were thus obtained in moderate yield. Subsequent nitrosation at the 5-position with alkyl nitrites (menthyl nitrite or amyl nitrite), gave the desired nitroso compounds **8a-i**. The 5-nitroso derivative **8g** was obtained after (Boc)₂O protection of compound **7g**, followed by nitrosation and subsequent deprotection of the amino group (Scheme 2).

Scheme 2. Reagents and conditions: i) (Boc)₂O, THF, RT, 2 h; ii) menthyl nitrite, DMSO, RT, 18 h; iii) TFA, CH₂Cl₂, RT, 2 h.

The final products (**9a-i**) were prepared by treating the nitroso derivatives (**8a-i**) with (diacetoxyiodo)benzene (IBA) and cyanamide (NH₂CN) in dry CH₃CN.^[16]

In the ¹H NMR experiments reported for the 5-nitroso derivatives (**8a-i**), the resonance of the 4-NH₂ group was split into two neat signals, which were observed at around 8 and 10 ppm, respectively. This observation was already reported in the previous work^[7] and confirms the formation of an intramolecular hydrogen bond between the nitroso oxygen atom and one hydrogen of NH₂ group in the 4-position. In contrast, for the cyano-*NNO*-azoxy derivatives (**9a-i**), the signal of the 4-NH₂ group was reported as a broad singlet. In addition, ¹H and ¹³C NMR spectra of both nitroso and cyano-*NNO*-azoxy derivatives presented two sets of resonances. This can be ascribed to the significant π component of the C2-N bond, as a consequence of strong conjugation between the electron donating N groups (e.g. NHCH₃ $\sigma_p = -0.84$)^[14] and the strong electron withdrawing groups, the cyano-*NNO*-azoxy and the nitroso group respectively, with consequent restricted rotation around the C2-N bond at room temperature (Figure 1). This hypothesis was confirmed by a variable temperature NMR experiment (VT-NMR) performed on compound **8a** for which coalescence of the two sets of signals was observed at 125 °C.

Figure 1. Electronic conjugation between the electron releasing N group and the electron withdrawing NO or cyanoNNO-azoxy groups
















Table 1. Inhibitory activity of target compounds against CDK2.

Compound	R ¹	R ²	IC ₅₀ (μM) ^{[a], [b]}
1		NO	2.2
3	NH ₂	-N(O)=N-CN	0.94
8a		NO	0.61
9a		-N(O)=N-CN	0.45
8b		NO	0.16
9b		-N(O)=N-CN	0.30
8c		NO	0.84
9c		-N(O)=N-CN	0.55
8d		NO	4.02
9d		-N(O)=N-CN	2.19
8e		NO	24.5
9e		-N(O)=N-CN	12.9
8f		NO	0.59
9f		-N(O)=N-CN	0.42
8g		NO	35% at 100 μM
9g		-N(O)=N-CN	66
8h			9% at 100 μM
9h			65.5
8i			49% at 100 μM
9i			54% at 100 μM

^[a] All IC₅₀ or % inhibition values are results obtained from n = 2 determinations. CDK-inhibition was determined at a minimum of five different inhibitor concentrations. ^[b] CDK assay conducted at 12.5 μM of ATP – full details in reference.^[17]

The new series of the 5-(cyano-*NNO*-azoxy) substituted compounds and of the related 5-nitroso precursors were evaluated for their CDK2 inhibitory activity using published procedures.^[18] The results, expressed as IC₅₀, are shown in Table 1 together with the inhibitory potency of compounds **1** and **3** as references. The potency in the 5-nitroso series exhibits the order **8b**>**8f**>**8a**>**8c**>**1**>**8d**>**8e**>**8i**>**8g**>**8h**. Analysis of the data shows that the introduction of the hydroxyethyl group at the 2-NH₂ of **1** (**8a**) increases the inhibitory potency by about three-fold, whilst the introduction of the hydroxypropyl substructure gives rise to **8f**, which is about four-fold more potent than the reference. Also, the presence of the 2-hydroxy-1-methylethyl moiety (as in **8b**, **8c**) induces a potency increase that is particularly evident in the *S*-stereoisomer (**8b**). As for compounds **8d**,**e**,**g**, the activity decreases with the growing of

the substituent in the 2-position. This is probably due to the weakening for steric reasons of the hydrogen bond between the 2-NH group of the compounds and the CO of the Leu-83 residue in the enzyme and to the fact that, due to the partially hindered rotation around C2-NH bond, one of the two conformers is unable to give this interaction. As expected, compounds **8h**,**i** displayed very feeble activity due to the absence of NH. The potencies and the SAR in the 5-(cyano-*NNO*-azoxy) series (**9a**-**i**) closely paralleled what was found in 5-nitroso series. Again, the most active substance **9b** bears the 2-hydroxy-1-methylethyl moiety at the 2-position and is about three-fold more active than the reference compound **3**.

The study reported in this paper extends the findings of the previous investigation.^[7] A series of *N*²-substituted derivatives of the reference compound **1** was synthesized in order to explore structure-activity relationships concerning the substitution at this nitrogen position with aliphatic amino substituents present in relevant CDK inhibitors. Even though no significant improvements were achieved in term of biological activity, the SARs and understanding of the criteria for achieving CDK2 inhibitory activity were enhanced. Introduction of the 5-(cyano-*NNO*-azoxy) function gave no significant improvement comparing to the corresponding 5-nitroso derivatives. However, the cyano-*NNO*-azoxy group is a suitable replacement for the nitroso group at 5-position, able to maintain CDK2 inhibitory activity. Since these two moieties are endowed with different chemical and physical-chemical properties, they should give rise to two different classes of inhibitors, which should display different ADMET profiles worthy of additional investigation.

Acknowledgements

This study was supported by University of Turin, Ricerca Locale 2014. The authors thank Cancer Research UK for financial support, the EPSRC National Mass Spectrometry Service at the University of Wales (Swansea) for mass spectrometric determinations and Prof. Alberto Gasco for the helpful discussions.


Keywords: Cyclin Dependent Kinases (CDK) • Anti tumor agents • CDK Inhibitors • Substituted pyrimidines • Nitrosation

References:

- [1] M. Malumbres, A. Carnero, *Nat. Rev. Cancer* **2009**, *9*, 153-166.
- [2] M. Malumbres, M. Barbacid, *Trends Biochem. Sci.* **2005**, *30*, 630-641.
- [3] F. Marchetti, K. L. Sayle, J. Bentley, W. Clegg, N. J. Curtin, J. A. Endicott, B. T. Golding, R. J. Griffin, K. Haggerty, R. W. Harrington, V. Mesguiche, D. R. Newell, M. E. M. Noble, R. J. Parsons, D. J. Pratt, L. Z. Wang, I. R. Hardcastle, *Org. Biomol. Chem.* **2007**, *5*, 1577-1585.
- [4] F. Marchetti, C. Cano, N. J. Curtin, B. T. Golding, R. J. Griffin, K. Haggerty, D. R. Newell, R. J. Parsons, S. L. Payne, L. Z. Wang, I. R. Hardcastle, *Org. Biomol. Chem.* **2010**, *8*, 2397-2407.
- [5] V. Krystof, S. Uldrijan, *Curr. Drug Targets* **2010**, *11*, 291-302.
- [6] C. E. Arris, F. T. Boyle, A. H. Calvert, N. J. Curtin, J. A. Endicott, E. F. Garman, A. E. Gibson, B. T. Golding, S. Grant, R. J. Griffin, P. Jewsbury, L. N. Johnson, A. M. Lawrie, D. R. Newell, M. E. M. Noble, E. A. Sausville, R. Schultz, W. Yu, *J. Med. Chem.* **2000**, *43*, 2797-2804.
- [7] D. Boschi, P. Tosco, N. Chandra, S. Chaurasia, R. Fruttero, R. J., Griffin, L. Z. Wang, A. Gasco, *Eur. J. Med. Chem.* **2013**, *68*, 333-338.

- [8] A. Gasco, A. Serafino, V. Mortarini, E. Menziani, M. A. Bianco, J. Ceruti Scurti, *Tetrahedron Lett.* **1974**, *15*, 3431-3432.
- [9] R. Fruttero, R. Calvino, A. Di Stilo, A. Gasco, I. Galatulas, R. Bossa, *Pharmazie* **1988**, *43*, 499-500.
- [10] R. Fruttero, C. Tironi, R. Calvino, *Pharmazie* **1988**, *43*, 551-552.
- [11] A. M. Caccuri, G. Ricci, A. Desideri, M. Buffa, R. Fruttero, A. Gasco, P. Ascenzi, *Biochem. Mol. Biol. Int.* **1994**, *32*, 819-829.
- [12] A. M. Gasco, A. Di Stilo, R. Fruttero, G. Sorba, A. Gasco, R. Budriesi, A. Chiarini *Med. Chem. Res.* **1993**, *3*, 34-43.
- [13] F. G. Hansske, W. Simon, **2005**, DE102004017174.
- [14] C. Hansch, A. J. Leo in *Substituent constant for correlation analysis in chemistry and biology, Chapter VI*. New York, John Wiley and Sons, **1979**, 49-50.
- [15] R. Calvino, R. Fruttero, A. Garrone, A. Gasco, *Quant. Struct.-Act. Relat.* **1988**, *7*, 26-30.
- [16] R. Fruttero, G. Mulatero, R. Calvino, A. Gasco, *J. Chem. Soc., Chem. Commun.* **1984**, *5*, 323-324.
- [17] I. R. Hardcastle, C. E. Arris, J. Bentley, T. Boyle, Y. Chen, N. J. Curtin, J. A. Endicott, A. E. Gibson, B. T. Golding, R. J. Griffin, P. Jewsbury, J. Menyerol, V. Mesguiche, D. R. Newell, M. E. M. Noble, D. J. Pratt, L. Z. Wang, H. Whitfield, *J. Med. Chem.* **2004**, *47*, 3710-3722.
- [18] J. Vesely, L. Havlicek, M. Strnad, J. J. Blow, A. Donella-Deana, L. Pinna, D. S. Letham, J. Y. Kato, L. Detivaud, S. Leclerc, L. Meijer, *Eur. J. Biochem.* **1994**, *224*, 771-786.

Entry for the Table of Contents



Starting from compound NU6027, a series of 2,4-diamino-5-nitrosopyrimidines was synthesized. SAR studies of this class of compounds led to enhanced understanding of the criteria to achieve CDK2 inhibitory activity. Cyano-*NNO*-azoxy substituent was confirmed to be a valuable alternative for 5-nitroso group.